Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2023	FY 2023
Period Ending	Mar 20, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Cap	25	14	10	38,775	113,519	-
Market Cap Growth	156.24%	38.31%	-99.97%	-65.84%	-	-
Enterprise Value	1.58	-0.16	-2.33	38,763	113,496	0
Last Close Price	4.61	7.10	9.20	26.40	83.88	-
PE Ratio	-	-30.87	-0.49	-1320.00	-	-
PS Ratio	1.58	0.90	-	-	624279.06	-
PB Ratio	0.80	0.74	0.58	1761.64	2891.81	-
P/TBV Ratio	0.40	0.61	0.44	1761.64	-	-
P/FCF Ratio	-	181.89	-0.69	-2648.95	-7564.51	-
P/OCF Ratio	-	181.89	-0.69	-2648.95	-7565.04	-
EV/Sales Ratio	0.11	-0.01	-	-	624153.77	-
EV/EBITDA Ratio	-	0.35	0.14	-1818.16	-6064.45	-
EV/EBIT Ratio	-	0.14	0.13	-1763.31	-6064.45	-
EV/FCF Ratio	-	-2.12	0.16	-2648.14	-7562.99	-
Debt / Equity Ratio	-	0	0.01	0.01	0.01	-
Debt / EBITDA Ratio	-	-0.25	-0.01	-0.02	-0.03	-
Debt / FCF Ratio	-	1.51	-0.02	-0.02	-0.03	-
Net Debt / Equity Ratio	-0.75	-0.74	-0.71	-0.53	-0.58	-
Net Debt / EBITDA Ratio	7.62	30.23	0.72	0.55	1.21	-
Net Debt / FCF Ratio	9.39	-182.50	0.84	0.80	1.51	-
Asset Turnover	0.55	0.56	0	0	0.01	-
Quick Ratio	9.00	3.37	3.33	4.57	12.02	-
Current Ratio	9.04	3.56	3.45	4.87	12.46	-
Return on Equity (ROE)	-25.50%	-2.03%	-78.44%	-69.80%	-96.84%	-
Return on Assets (ROA)	-12.13%	-1.77%	-63.30%	-59.34%	-82.52%	-
Return on Invested Capital (ROIC)	-28.09%	-4.61%	-141.38%	-129.20%	-186.10%	-
Return on Capital Employed (ROCE)	-14.27%	-4.69%	-72.08%	-64.13%	-87.59%	-
Earnings Yield	-23.88%	-3.24%	-202.39%	-0.08%	0.00%	-
FCF Yield	-9.96%	0.55%	-144.55%	-0.04%	-0.01%	-
Buyback Yield / Dilution	-85.87%	-10.88%	-148.76%	-0.01%	-0.02%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q